EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biologic Treatments for Asthma and Chronic Obstructive Pulmonary Disorder

Misa Kusumoto, Bryan J. Mathis

Allergies · 2021

DOI: 10.3390/allergies1020007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergies, 2021. Verfasst von Misa Kusumoto und 1 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global COVID-19 pandemic has brought respiratory disease to the forefront of public health, but asthma prevalence has been rising globally for decades. Asthma is mediated by errant immune activation and airway remodeling, but the influences of environment, nutrition, and comorbidities (e.g., asthma-chronic obstructive pulmonary disorder-overlap [ACO]) are still poorly understood. Even as a new generation of biologic-based treatments offer better airway control and reductions in mortality, a lack of prophylactic treatments and mechanistic understanding complicates efforts to prevent pathogenesis. This review will explicate and synthesize current knowledge on the effect of ACO and biologics (omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab) on pathogenesis, treatment, and prognosis.

Zitieren

APA

Kusumoto, M., & Mathis, B. J. (2021). Biologic Treatments for Asthma and Chronic Obstructive Pulmonary Disorder. Allergies. https://doi.org/10.3390/allergies1020007

Vancouver

Kusumoto M, Mathis BJ. Biologic Treatments for Asthma and Chronic Obstructive Pulmonary Disorder. Allergies. 2021. doi:10.3390/allergies1020007

BibTeX
@article{Kusumoto2021,
  author = {Kusumoto, Misa and Mathis, Bryan J.},
  title = {Biologic Treatments for Asthma and Chronic Obstructive Pulmonary Disorder},
  journal = {Allergies},
  year = {2021},
  doi = {10.3390/allergies1020007}
}
Kostenlos starten →